FDA clinical trials
In the past months we’ve seen the approval of several drugs with limited data. Possibly this is the ‘natural’ consequence of both the Fast Track Designation and the Adaptative Pathway solutions that have been accepted.
In the past months we’ve seen the approval of several drugs with limited data. Possibly this is the ‘natural’ consequence of both the Fast Track Designation and the Adaptative Pathway solutions that have been accepted.
Taking part in the XXXVII Jornadas de economia de la salud.
Dr. Solà-Morales Serra has participated in the formulation of a new study called, Assessing the Value of New Antibiotics: Additional Elements of Value for Health Technology Assessment Decisions.
Dr. Solà-Morales Serra has participated in the formulation of a new study that explains the innovative approach of drug’s public procurement.
On date 03 of May of 2017, Health innovation technology transfer has been selected by Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS).
The objective of this workshop was achieving a multistakeholder work table discussing about issues related to drugs pricing, focusing the horizon scanning, access to innovation, current and future role of insurances and private providers.
Entrevista en salud+economia
Article d’opinió publicat a El Periódico el 18/3/2016. Descarrega’l en pdf.